Clinical Trial Details

Short Title
A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects with Refractory Chronic Lymphocytic Leukemia
Official Title

A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects with Refractory Chronic Lymphocytic Leukemia

Description

The purpose of this study is to test the safety of the research study drug, dinaciclib (MK-7965) and to compare the effectiveness of dinaciclib and ofatumumab in treating patients with Chronic Lymphocytic Leukemia (CLL). This is a research study to test a drug that has not yet been approved for sale. Ofatumumab may be available by prescription for the treatment of CLL. The use of ofatumumab for 12 months has not yet been approved.

Start Date
July 3, 2013
End Date
April 30, 2016
Gender Preference
None
Age Group
18 - 99 years
Principal Investigator
Thomas Carter, MD, PhD
Contact Info

Karen Parrott, 319-353-6347

Department
Department or Field of Study
Keywords
cancer ; carter ; chronic lymphocytic leukemia ; dinaciclib ; IRB#201210503 ; ofatumumab ; phase 3 ; phase III ;

We'd welcome your feedback!

Please help us improve your experience on our website by completing a brief survey

Yes, I'll give feedback No, Thanks

x